After Novavax (NVAX) announced results of the initial cohort of its COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial, BTIG analyst Thomas Shrader said the goal was to show that the immunogenicity of both the COVID-19 and Influenza vaccines was in the protective range and “interference” was not a strong factor. The first CIC data “looks unremarkable – exactly what we hoped for,” says the analyst, who adds that the “most positive signs from today’s data” were stronger immunogenicity for the Novavax flu vaccine for some antigens relative to the “gold-standard” flu vaccine FLUZONE-HD. The firm maintains its Buy rating and $19 price target on Novavax shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses’
- Novavax Reports Promising Phase 3 Vaccine Trial Results
- Novavax reports results from CIC, tNIV Phase 3 trial
- Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue